Maine § 22 §2673 Action against health care practitioner or health care provider license prohibited

Maine Statutes

§ 22 §2673 — Action against health care practitioner or health care provider license prohibited

Maine § 22 §2673

Title 22HEALTH AND WELFARE

Part 5FOODS AND DRUGS

Ch. 602-AACCESS TO INVESTIGATIONAL TREATMENTS FOR TERMINALLY ILL PATIENTS

This text of Maine § 22 §2673 (Action against health care practitioner or health care provider license prohibited) is published on Counsel Stack Legal Research, covering Maine primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Me. Rev. Stat. tit. 22, § 22 §2673 (2026).

Text

A licensing board may not revoke, refuse to renew or suspend the license of or take any action against a health care practitioner as defined in Title 24, section 2502, subsection 1-A based solely on the health care practitioner's recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product or device, as long as the recommendations are consistent with medical standards of care.
The licensing agency may not revoke, refuse to renew or suspend the license of or take any action against a health care provider as defined in Title 24, section 2502, subsection 2 based solely on the health care provider’s involvement in the care of an eligible patient using an investigational drug, biological product or device.

Free access — add to your briefcase to read the full text and ask questions with AI

A licensing board may not revoke, refuse to renew or suspend the license of or take any action against a health care practitioner as defined in Title 24, section 2502, subsection 1-A based solely on the health care practitioner's recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product or device, as long as the recommendations are consistent with medical standards of care.
The licensing agency may not revoke, refuse to renew or suspend the license of or take any action against a health care provider as defined in Title 24, section 2502, subsection 2 based solely on the health care provider’s involvement in the care of an eligible patient using an investigational drug, biological product or device.